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New Findings
r What is the central question of this study?
What is the functional relevance of OPN isoform expression in muscle pathology?
r What is the main finding and its importance?
The full-length human OPN-a isoform is the most pro-inflammatory isoform in the muscle
microenvironment, acting on macrophages and myoblasts in an RGD-integrin-dependent
manner. OPN-a upregulates expression of tenascin-C (TNC), a known Toll-like receptor 4
(TLR4) agonist. Blocking TLR4 signalling inhibits the pro-inflammatory effects of OPN-a,
suggesting that a potential mechanism of OPN action is by promoting TNC–TLR4 signalling.

Although osteopontin (OPN) is an important mediator of muscle remodelling in health and
disease, functional differences in human spliced OPN variants in the muscle microenvironment
have not been characterized. We thus sought to define the pro-inflammatory activities of
human OPN isoforms (OPN-a, OPN-b and OPN-c) on cells present in regenerating muscle.
OPN transcripts were quantified in normal and dystrophic human and dog muscle. Human
macrophages and myoblasts were stimulated with recombinant human OPN protein isoforms,
and cytokine mRNA and protein induction was assayed. OPN isoforms were greatly increased
in dystrophic human (OPN-a > OPN-b > OPN-c) and dog muscle (OPN-a = OPN-c). In
healthy human muscle, mechanical loading also upregulated OPN-a expression (eightfold;
P < 0.01), but did not significantly upregulate OPN-c expression (twofold; P > 0.05). In
vitro, OPN-a displayed the most pronounced pro-inflammatory activity among isoforms,
acting on both macrophages and myoblasts. In vitro and in vivo data revealed that OPN-a
upregulated tenascin-C (TNC), a known Toll-like receptor 4 (TLR4) agonist. Inhibition of TLR4
signalling attenuated OPN-mediated macrophage cytokine production. In summary, OPN-a
is the most abundant and functionally active human spliced isoform in the skeletal muscle
microenvironment. Here, OPN-a promotes pro-inflammatory signalling in both macrophages
and myoblasts, possibly through induction of TNC–TLR4 signalling. Together, our findings
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suggest that specific targeting of OPN-a and/or TNC signalling in the damaged muscle
microenvironment may be of therapeutic relevance.
(Received 25 February 2016; accepted after revision 15 July 2016; first published online 25 July 2016)
Corresponding author E. P. Hoffman: Associate Dean for Research, School of Pharmacy and Pharmaceutical
Sciences, Binghamton University - SUNY, P.O. Box 6000, Binghamton, N.Y. 13902-6000, USA,
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Introduction
Osteopontin (OPN), or secreted phosphoprotein 1
(SPP1), is a member of the small integrin-binding
ligand N-linked glycoprotein (SIBLING) protein family.
SIBLING family proteins are structurally characterized
by their small flexible structure and the presence
of an Arg-Gly-Asp (RGD) tripeptide, an authentic
integrin-binding sequence (Fisher et al. 2001). OPN is
a secreted protein with diverse physiological functions
influenced by multiple pre- and post-translational
modifications. Increasing importance has been attributed
to OPN as an immunoregulatory protein in inflammation
and tissue remodelling (acute and chronic) and cancer
(Shin, 2012; Bandopadhyay et al. 2014). However, the
amino acid sequence is relatively poorly conserved
between mice and humans (63% homology), with
the greatest degree of conservation occurring around
receptor binding sites (e.g. RGD domain) and proteolytic
cleavage sites. The human but not mouse gene shows
three alternatively spliced isoforms (Gimba & Tilli,
2013). Full-length OPN protein is designated OPN-a,
with a molecular weight of 54 kDa prior to extensive
post-translational modifications. OPN-b lacks exon 5
(50 kDa), and OPN-c lacks exon 4 (47 kDa) of the
seven exons.
All human OPN isoforms contain the RGD and
SVVYGLR integrin-binding peptide sequences (Yokosaki
et al. 1999), a CD44 binding domain, and thrombin
and matrix metalloproteinase cleavage sites. Unlike the
RGD integrin-binding peptide sequence, the SVVYGLR
integrin-binding site is exposed only upon thrombin
cleavage of OPN (Yokosaki et al. 1999). The three
spliced isoforms differ in protein cross-linking sites
(Gln residues) that undergo covalent polymerization by
transglutaminase 2, a difference that significantly alters
OPN function (Higashikawa et al. 2007; Nishimichi et al.
2011). Transglutaminase 2 catalyses OPN polymerization
at multiple Gln residues coded by exons 2–5 (Christensen
et al. 2014). The deleted exons 5 (OPN-b) and
4 (OPN-c) contain one and three Gln residues,
respectively, making the degree of isoform polymerization
proportional to the number of transglutamination sites,
with OPN-a > OPN-b > OPN-c (Nishimichi et al.
2011). Transglutamination of OPN is thought to modify
protein function by altering the conformational state of

OPN, thereby increasing its cell-binding and chemotactic
abilities (Kaartinen et al. 1999; Nishimichi et al. 2011).
Despite the widely characterized role of OPN as a
pro-inflammatory protein, little research has investigated
the function or expression patterns of OPN spliced
isoforms outside of the field of cancer biology. In
tumour cells, differential OPN isoform expression patterns
are related to cancer cell behaviours and pathological
outcomes such as proliferation, migration and metastasis
(Gimba & Tilli, 2013). In breast cancer cells, OPN-abut not OPN-c-transfected cells display signal transducer
and activator of transcription 1 & 3 (STAT1/3) DNA
binding (Shi et al. 2014). STAT1/3 activation occurs
in response to cytokines, such as interleukin (IL)-6,
suggesting that OPN isoforms may differentially modulate
inflammatory cytokine induction. However, the effects
of OPN isoforms on inflammatory signalling in other
cellular microenvironments, such as skeletal muscle,
remain unclear.
The role of OPN in muscle remodelling has received
increased interest as a result of three recent observations.
First, ablation of OPN expression in the mouse model
of Duchenne muscular dystrophy (dystrophin-deficient
mdx mice) improves disease pathology (Vetrone et al.
2009). Second, a genetic polymorphism in the human
OPN gene altering gene transcription is associated with
disease severity in Duchenne muscular dystrophy (DMD;
Pegoraro et al. 2011; Bello et al. 2015). Finally, the same
genetic polymorphism is associated with increased muscle
size (Hoffman et al. 2013) and increased damage in
response to eccentric contraction in young adults (Barfield
et al. 2014). In normal skeletal muscle in homeostatic
conditions, OPN expression is very low or undetectable.
Expression of OPN is rapidly induced in acute and
chronic muscle injury, with expression primarily localized
to infiltrating immune cells and proliferating myogenic
cells (Uaesoontrachoon et al. 2008; Zanotti et al. 2011;
Paliwal et al. 2012; Pagel et al. 2014). In myogenic cells,
OPN expression is upregulated with inflammatory stimuli
and degeneration/remodelling (Uaesoontrachoon et al.
2008; Paliwal et al. 2012). However, functional differences
between spliced isoforms in the regenerating muscle
microenvironment have not been characterized.
In healthy and diseased muscle (e.g. DMD),
macrophages are the predominant cellular infiltrate and
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express high levels of OPN (Hirata et al. 2003). Despite
increasing importance being attributed to OPN in muscle
remodelling, the relative contribution of spliced isoforms
to muscle remodelling has not been studied in either health
or disease. We thus sought to provide better definition
of the role of OPN spliced isoforms in the skeletal
muscle microenvironment by studying macrophage and
myoblast/muscle inflammatory signalling. We observed
that OPN-a is the most abundantly expressed isoform
in human muscle. In both macrophages and myoblasts,
OPN-a was the most pro-inflammatory spliced isoform.
Methods
Ethical approval

All tissue samples were obtained by protocols approved
by the Institutional Animal Care and Use Committee
or Institutional Review Board, for respective animal and
human studies at respective institutions. For human
studies, all participants consented to study participation
at the enrolling institution, and all study procedures
were conducted according to standards set forth by the
Declaration of Helsinki.
Human and canine skeletal muscle OPN expression
Human. All human muscle biopsies were obtained

by fine-needle biopsy of the vastus lateralis muscle
and flash-frozen for processing. Briefly, samples were
collected using local anaesthetic (1% lidocaine).
Duchenne muscular dystrophy, Becker’s muscular
dystrophy (BMD) and control human muscle biopsies
were archival specimens from a tissue bank at the
Children’s National Medical Center. These samples
were obtained from consenting subjects and/or their
legal guardian, if under the age of 18 years. All
subjects were male owing to the X-linked nature
of DMD. For OPN isoform detection, the human
forward primer (ATTGCAGTGATTTGCTTTTGC) was
designed against human exon 2 and the reverse primer
(GCAACCGAAGTTTTCACTCC) against exon 6.
For loading stress studies, biopsies were obtained
from healthy male (n = 11) and female (n = 11)
human subjects (age 57 ± 3 years) immediately
before and 24 h after loading-induced stress. Here,
subjects performed unaccustomed resistance exercise, by
performing 9–10 repetitions at 65% one-repetition
maximum. All subjects were > 18 years old and consented
to study participation at the University of Alabama,
Birmingham (Stec et al. 2015). qPCR was performed
by Taqman gene array on a StepOnePlus Real-Time
PCR System (Applied Biosystems, Foster City, CA,
USA). Here, glyceraldehyde-6-phosphate dehydrogenase
(GAPDH) was used as an endogenous control.
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Canine. Muscle samples were taken at either biopsy or

post mortem from the cranial sartorius (CS), vastus
lateralis (VL) and long digital extensor (LDE) from the
opposite limbs of golden retriever muscular dystrophy
(GRMD) dystrophin-deficient dogs (n = 8) and wild-type
littermates (n = 4) at 4–9 weeks (early stage disease) and
6 months (symptomatic disease), as previously described
(Nghiem et al. 2013). All dogs were used and cared for
according to principles outlined in the National Research
Council Guide for the Care and Use of Laboratory
Animals. Dogs were housed at the Kornegay laboratory
at either the University of Missouri or the University of
North Carolina at Chapel Hill. All animals were given ad
libitum access to food and water. The GRMD dogs were
identified at 1 day of age based on a dramatic elevation
of serum creatine kinase. Genotype was confirmed
by PCR when creatine kinase results were ambiguous.
Characteristic clinical signs subsequently developed. For
muscle biopsy, dogs were given a general preanaesthetic
regimen comprising acepromazine maleate, butorphanol
and atropine sulfate and masked and maintained under
general anesthesia with sevoflurane. On average, 400 mg
of tissue was sampled per dog.
For dystrophic human and dog samples, hypoxanthine
phosphoribosyltransferase 1 (HPRT1) was used as an
endogenous control for expression of OPN isoforms.
RNA was isolated by TRIzol extraction, and cDNA
synthesis was performed using an Applied Biosystems’
High Capacity cDNA Reverse Transcription Kit (Life
Technologies) according to methods described previously
(Nghiem et al. 2013). Briefly, for PCR analyses, cDNA was
incubated at 90°C for 1 min; a multiplex reaction was then
carried out with OPN and HPRT1 probes according to the
manufacturer’s instructions using AccuPrime SuperMix
II (Invitrogen). Reactions were performed in triplicate
for samples from both normal (n = 4; all male) and
GRMD (n = 8; n = 4 male and n = 4 female) cDNA
(CS, LDE and VL) at 4–9 weeks and 6 months. The PCR
conditions for human samples were 30 cycles at 94°C for
5 min, 94°C for 30 s, 60°C for 1 min, 72°C for 30 s, and
72°C for 7 min. OPN mRNA isoform bands were detected
with GeneSnap software and quantified and normalized to
HPRT1 in GeneTools software (Syngene, Frederick, MD).
Human primary monocyte-derived macrophages

Consenting
healthy
adult
men
not
taking
anti-inflammatory or immunoregulating medications
underwent venipuncture for the isolation of primary
human monocytes by negative selection. All subjects
consented to participate in this study conducted
at the Children’s National Medical Center. To obtain
monocytes, venous blood was collected in sodium heparin
vacutainers and immediately processed for isolation of
peripheral blood-derived mononuclear cells via density
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centrifugation using Ficoll Paque Plus (GE Lifesciences,
Marlborough, MA, USA). Monocytes were then isolated
from the peripheral blood-derived mononuclear cell
layer via negative magnetic selection for CD14+ cells,
without CD16+ cell depletion (StemCell Technologies,
Vancouver, BC, Canada). Monocyte cell identity was
confirmed via staining for human CD14 and CD16 (BD
Biosciences). Negative selection for monocytes resulted
in a cell population of 94% purity as defined as follows:
CD14hi CD16lo , CD14lo CD16hi and/or CD14hi CD16hi as
determined by fluorescence-activated cell sorting (FACS).
Monocytes were plated at a density of 100,000 cells per
well in 96-well plates for culture in DMEM–F12 media
containing 1% penicillin–streptomycin and 10% fetal
bovine serum, and cultured with 50 ng ml−1 human
recombinant macrophage colony-stimulating factor
(M-CSF) (R&D Systems, Minneapolis, MN, USA). Cells
were cultured for 5 days at 37 °C in air supplemented with
5% CO2 , in order to differentiate cells into primary human
macrophages. Human monocyte-derived macrophages
were phenotypically characterized by an increase in size
and the formation of cytoplasmic projections.
Recombinant protein derivation

Human OPN isoforms (OPN-a, -b and -c) were
expressed as glutathione S-transferase (GST) fusion
proteins in Escherichia coli with pGEX6P plasmid,
affinity purified and cleaved from GST according
to previously described methods (Nishimichi et al.
2011). Recombinant human OPN-a proteins containing:
(i) RGD (arginine-glycine-aspartic) acid residues; and
(ii) OPN-a with the RGD domain mutated to KAE
[lysine-alanine-glutamic; RGD→KAE (OPN-a-KAE)]
were a kind gift from Dr Larry Fisher at the National
Institutes of Health. Briefly, recombinant proteins were
generated by subcloning OPN-a-RGD and OPN-a-KAE
cDNA into pAd/CMV/V5-DEST adenovirus vectors in
HEK293 cells. Viral transfection of human stromal
fibroblasts was then used to generate recombinant
proteins, which were purified via column chromatography
(Fedarko et al. 2000). Briefly, the proteins were
purified using Sartobind Q strong basic anion exchanger
(Sartorius, Göttingen, Germany). Here, the Sartobind Q
15 membrane was equilibrated with 50 ml PBS prior to
sample filtration. The membrane was then washed with
8 M urea, 0.2% β-mercaptoethanol–PBS and 100 ml PBS.
A linear salt gradient to 2.0 M NaCl–PBS was used to purify
proteins to 95% purity as measured by Stains-All (Sigma,
St Louis, MO, USA).
Human macrophage stimulation

Human recombinant OPN proteins showed evidence of
endotoxin contamination (Pierce LAL assay; Thermo

Exp Physiol 101.10 (2016) pp 1285–1300

Scientific, Waltham, MA, USA). To inhibit endotoxin
effects on assays, we pretreated all samples with
polymixin-B (PMB; InvivoGen, San Diego, CA, USA).
This was shown to inhibit the effects of E. coli-derived
lipopolysaccharide (LPS; tested range 10–100 ng ml−1 )
on human macrophages. Macrophages were pretreated
with 100 μg ml filtered PMB sulfate in PBS 30 min
prior to stimulation with OPN (InvivoGen). Polymixin-B
is a positively charged cyclic polypeptide that binds
to and inhibits the actions of the negatively charged
and bioactive lipid A tail of endotoxin (Cavaillon &
Haeffner-Cavaillon, 1986). The pretreatment of cells with
PMB was optimized through testing of IL-6 and tumour
necrosis factor-α secretion from human macrophages
assayed by enzyme-linked immunosorbent assay ELISA
and FACS bead array. Endotoxin-depleted recombinant
human and murine OPN-a was also obtained for
testing and optimization of inflammatory responses (R&D
Systems).
For mRNA assays, macrophages were treated with
OPN proteins for 4 h. For protein assays, macrophages
were treated with OPN proteins for 24 h. For protein
assay by ELISA, R&D Duo Set kits were used (R&D
Systems).
Nanostring expression profiling

After culturing for 5 days with 50 ng ml−1 human
M-CSF, fresh human monocyte medium was added, and
primary human monocyte-derived macrophages were
stimulated for 4 h with human recombinant OPN proteins
for expression profiling by Nanostring according to
methods described previously (Dillingham et al. 2015).
Briefly, cells were harvested in cell stripper (Cellgro,
Manassas, VA, USA), washed and resuspended in RLT
Buffer (Qiagen, Hilden, Germany). Messenger RNA
molecule counting was performed on 10,000 macrophages
per treatment condition using a custom Nanostring
probe set and a NanoString nCounter analytics system
(Nanostring Technologies, Seattle, WA, USA). Eight
negative control probes (targeting RNA sequences not
expressed in humans) were used to adjust for background
noise. Six positive probes (targeting housekeeping gene
transcripts) were included in each probe set for initial
content normalization, using geometric means of control
transcript counts as a normalization factor. Additional
normalization was performed against reference genes that
were abundantly expressed (>2 SD over negative control
probes) and did not display variability between treatment
conditions and donors (P > 0.05). Based on these
normalization procedures, GIGYF2, RMBX2, STK35 and
TOX4 were used as normalization controls for macrophage
studies, and HDAC3, RBMX2, STK35, TOX4 and USP4 for
muscle studies.
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Human myogenic cell culture

Immortalized human myoblasts were a gift from Dr
Vincent Mouly at the Centre for Research in Myology
in Paris, France. These primary human myoblasts were
derived from a healthy 25-year-old female subject and
immortalized according to previously described methods
(Di Donna et al. 2003). Muscle was obtained via
fine-needle biopsy of the vastus lateralis for cell isolation.
Once immortalized, cells were grown in skeletal muscle cell
media (Promocell, Heidelberg, Germany) supplemented
with 20% fetal bovine serum at 37°C in air supplemented
with 5% CO2 . Cells were plated overnight prior to
stimulation with OPN.
Phagocytosis assay

Freshly isolated primary human monocytes were cultured
in human macrophage media without added M-CSF and
left to adhere overnight at 37°C in air supplemented with
5% CO2 . Cells were then washed, and fresh medium was
added 1 h before 30 min pretreatment with PMB. Cells
were then stimulated for 2 h with recombinant OPN
proteins. Following stimulation with OPN, fluorescently
conjugated E. coli particles (K-12 strain) were suspended
in Hanks’ balanced salt solution and added to the solution,
according to the manufacturer’s instructions (Vybrant
Phagocytosis Assay Kit; Molecular Probes, Eugene, OR,
USA). After an additional 2 h incubation period, cells
were washed to remove non-phagocytosed E. coli particles,
and cellular fluorescence of non-viable cells was quenched
with Trypan Blue for 1 min. The Trypan Blue solution was
then aspirated. To determine cellular uptake of fluorescent
E. coli particles, fluorescence was measured first on a
fluorescence plate reader using wavelengths of 485 nm
for excitation and 525 nm for emission, and a repeat
experiment was performed by FACS using the fluorescein
isothiocyanate (FITC) channel (FL1). All experiments
were run in technical replicates of n = 5, according to the
manufacturer’s instructions. For FACS reading, cells were
harvested with cell stripper, centrifuged, and resuspended
in FACS buffer. All fluorescence measures were normalized
for background fluorescence (E. coli particles only)
prior to normalization to vehicle control cells (PMB
treated).
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(GeneCopoeia; 50 μg total in 100 μl PBS) was injected
into the right tibialis anterior (TA) muscle of 3-month-old
male BLA/J mice (n = 3). The TA muscle was chosen
because it is accessible by injection without surgery
and is relatively homogeneous in fibre-type composition
(predominantly fast twitch). Given that surgery is well
known to induce inflammation, we wished to avoid
this added confounding variable, because inflammation
was a key end point. The contralateral left TA muscle
was injected with 50 μg of scrambled (empty) plasmid
(GeneCopoeia, Rockville, MD, USA) and used as a
vehicle and injection control. Tibialis anterior muscles
were harvested 7 days postinjection for microarray
expression profiling. The bellies of the TA muscles were
sectioned, and total RNA was extracted from 50 muscle
sections using TRI reagent (Sigma-Aldrich, St Louis, MO,
USA). Illumina beadchip microarray was performed on
the extracted mRNA according to previously described
methods (Uaesoontrachoon et al. 2013). Data were
analysed through use of Ingenuity Pathway Analysis
software. A P value of 0.05 and fold change of 1.5
between vector- and OPN-a-injected groups was used as
a cut point for pathway analysis.
Statistical analyses

Statistical significance between treatment conditions
was assessed via Student’s t tests, unless otherwise
indicated. Statistical significance was set at P < 0.05.
For Nanostring expression profiling, ANOVA was
performed, and differences between groups were
assessed using Bonferonni correction for multiple testing
(cytokines and doses) through use of Partek Genomics
Suite software, version 6.6 (St. Louis, MO, USA.).
Additionally, Student’s paired t tests were used to
examine single-dose responsiveness between donors,
where paired comparisons between treatment per donor
was performed. For transient transfection experiments,
statistical powering for microarray was based on initial
measures of inflammation (inflammatory foci per tissue
cross-section). For these analyses, a sample size of n = 3
was considered sufficient for statistical powering (Cohen’s
d = 2.9).
Results

Intramuscular OPN transfection and expression
profiling

Prominent expression of OPN isoforms in dystrophic
muscle

Use of mice for research was approved and conducted
according to the Children’s National Medical Center
Institutional Animal Care and Use Committee guidelines.
Mice were given ad libitum access to food and
water. Animals were euthanized by CO2 overdose.
For transfection experiments, murine OPN-a plasmid

Spliced OPN isoform (Fig. 1A) expression patterns
in dystrophic muscle were determined by RT-PCR in
dystrophin-deficient human and dog muscle. Consistent
with previous reports, OPN was scarcely expressed in
dystrophin-sufficient muscle but highly expressed in
dystrophic muscle, in both humans and dogs (Porter
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et al. 2004; Zanotti et al. 2011; Kornegay et al. 2014;
Fig. 1B and C). In patients with DMD, all three OPN
RNA isoforms were observed; OPN-a (full length),
OPN-b (minus exon 5) and OPN-c (minus exon 4),
with relative levels of OPN-a > OPN-b > OPN-c
(Fig. 1B). In GRMD dog muscle, OPN-a and OPN-c were

A

1

2

3
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expressed at similar levels, and OPN-b was not recognized
(Fig. 1C).
To determine whether the relative levels of these
isoforms changed as a function of age or muscle
histological severity, we studied the GRMD dog model
of DMD, a spontaneously occurring large-animal model
4
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Q QQ
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Figure 1. Alternatively spliced osteopontin isoforms are expressed in dystrophic muscle
A, OPN spliced isoform transcript structure. The blocks in this figure represent exons and the
lines represent introns. Here, OPN-a is full length (top), OPN-b is missing exon 5 (middle), and
OPN-c is missing exon 4 (bottom). B, osteopontin isoform transcript expression in muscle biopsies
of three dystrophin-deficient Duchenne muscular dystrophy (DMD) patients [D1–D3], and three
dystrophin-sufficient control subjects [N1–N3] as determined by RT-PCR. Minimal expression is detected
in dystrophin-sufficient muscle, whereas all three isoforms are expressed in DMD muscle (full-length
OPN-a, OPN-b lacking exon 5, and OPN-c lacking exon 4). C, dog dystrophin-deficient muscle likewise
shows no detectable expression in dystrophin-sufficient littermates (N1), but high expression of OPN-a
and OPN-c in dystrophin-deficient golden retriever muscular dystrophy (GRMD) vastus lateralis muscle
(D1). D, RT-PCR analysis of muscle biopsies from three muscles and two age points (4-9 W, 4–9 weeks
old; and 6 M, 6 months old) in dystrophin-sufficient (N) and -deficient (D) dogs shows elevated OPN
mRNA in all dystrophic muscles at all age points. An increase in OPN-a mRNA levels with age is seen in
the three muscle groups tested (CS, cranial sartorius; LDE, long digital extensor; and VL, vastus lateralis).
Here, OPN-a mRNA levels were correlated with both age and severity of muscle involvement (CS, mildly
affected; and LDE and VL, severely affected). Triplicates are shown per sample. Significant difference
between dystrophic and non-dystrophic littermates: ∗∗ P < 0.01. Significant differences with age per
muscle group: # P  0.05 and ## P  0.01 (GRMD, n = 8; and dystrophin-sufficient littermates, n = 4).
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that shares many clinical and histological features of the
human disease (Kornegay et al. 2012). Expression of OPN
in the severely affected VL and LDE and the mildly
affected CS of GRMD dogs (Nghiem et al. 2013) was
assessed by qRT-PCR. This differential involvement of
muscles in GRMD is shared with human DMD patients
(Li et al. 2015). OPN transcripts increased as a function of
both age and muscle histological severity (Fig. 1D). Here,
OPN-c expression closely paralleled OPN-a expression
(not shown).
Human OPN-a and OPN-c isoform ratios change
with DMD severity and mechanical loading

To confirm the relevance of our PCR findings, we
performed Nanostring expression profiling on VL biopsies
from a larger cohort of human DMD (dystrophin
deficient) and BMD patients (partly dystrophin deficient).
Total OPN (all isoforms) and OPN-c levels were quantified
because the sequences of OPN-a and OPN-b displayed
too high an overlap for accurate sequence coverage by
Nanostring expressing profiling. Histology (Haematoxylin
and Eosin) was performed on muscle biopsy sections prior
to analyses. Histology was used to group samples according
to histological severity as determined by the number of
degenerating and regenerating fibres and inflammatory
foci per image field. No significant differences in total
OPN (sequence specific to OPN exon 7) or OPN-c
(sequence specific to exons 3–5, with exon 4 deleted)
were observed between patients based on diagnosis (DMD
versus BMD) or histological severity (mild versus severe;
not shown). However, when comparing the ratio of OPN-c
expression relative to all forms of OPN, DMD patients
displayed a higher ratio of total OPN relative to OPN-c
expression. Additionally, when grouping DMD and BMD
patients based on histological severity, increased severity
was associated with a higher ratio of total OPN relative
to OPN-c expression (Fig. 2A). This suggests that the
expression of OPN-a and OPN-b isoforms, not OPN-c,
is more closely associated with dystrophic pathological
severity.
Given that OPN is expressed during muscle
degeneration and remodelling, which is a prominent
feature of DMD, we sought to characterize OPN isoform
expression in healthy human muscle in response to a
mild inflammatory stimulus. Subjects performed one bout
of unaccustomed mechanical loading (knee extension),
and muscle biopsies of the vastus lateralis muscle were
taken before and 24 h after loading. This stimulus
was previously observed to induce mild muscle damage
and inflammation (Merritt et al. 2013). Here, we
observed, similar to DMD patient muscle biopsies, that
OPN-a, not OPN-c, was the most prominent isoform
upregulated in response to mechanical loading. Expression
of OPN-a increased approximately eightfold (P < 0.05)
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with mechanical loading. Expression of OPN-c increased
approximately two-fold, but did not reach statistical
significance (P > 0.05). Expression levels of OPN-a were
also correlated with induction of the pro-inflammatory
proteins tenascin-C (TNC), a Toll-like receptor 4 (TLR4)
agonist (Midwood et al. 2009), and IL-1β. Levels of OPN-c
were not correlated with expression of either of these
pro-inflammatory proteins (Fig. 2B).
Differential cytokine induction by OPN-a relative
to OPN-b and OPN-c

To understand the role of elevated OPN isoform
expression in dystrophic muscle, we next observed the
effects of each human OPN isoform on macrophage
activation, because macrophages extensively infiltrate
dystrophic muscle and play crucial roles in muscle
remodelling. Primary human macrophages derived from
circulating monocytes from normal volunteers (n = 4
healthy male donors) were incubated with recombinant
human OPN protein isoforms (Yokosaki et al. 1999).
Cells were pretreated with PMB to inhibit the effects
of any endotoxin contamination within the recombinant
proteins. Cells were then stimulated with recombinant
OPN isoforms (1.0 μg ml−1 ) or vehicle (PMB) for 4 h.
Messenger RNA molecule counting (Nanostring) was
performed to quantify the expression of the following
pro-inflammatory and pro-fibrotic transcripts: CCL5,
IL-1β, IL-10, IL-15, IFITM1, TNC and transforming
growth factor β (TGFβ) isoforms 1–3. The transcripts
included in the custom Nanostring panel were chosen
based on previous microarray data demonstrating the
acute upregulation of these transcripts in response to
pro-inflammatory and pro-fibrotic stimuli and have
been published elsewhere (Dillingham et al. 2015).
OPN-a induced the greatest amount of pro-inflammatory
transcript induction (Fig. 3A). Significant main and
between-treatment effects were observed when comparing
differences in cytokine production induced by OPN-a,
OPN-b and OPN-c as determined by ANOVA testing, with
Bonferroni correction (main effects: CCL5, P < 0.001;
IL-1β, P < 0.001; IL-10, P = 0.009; TNC, P = 0.015;
and IFITM1, P = 0.010; and between-group effects for
all proteins: OPN-a versus OPN-b, P < 0.01; and OPN-a
versus OPN-c P < 0.001). Expression of TGFβ-1 did not
change in response to OPN treatment and TGFβ-2/3
isoform expression was not detectable (not shown).
Together these data suggest that OPN-a promotes strong
cytokine induction from human macrophages, whereas
OPN-b and OPN-c induce less inflammatory activity.
OPN contains an RGD integrin-binding domain on
exon 6, which is conserved in all three spliced isoforms. To
determine whether the pro-inflammatory activity of OPN
was mediated by integrins that bind to the RGD site, we
used mutant OPN, in which RGD was changed to KAE
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(OPN-a-KAE; Young et al. 1990). RGD-sufficient OPN-a
significantly increased the expression of inflammatory
cytokines, whereas OPN-a-KAE displayed attenuated
effects (Fig. 3B).
So far, we have shown that OPN is upregulated in
dystrophic muscle and exerted pro-inflammatory effects
on macrophages. To gain a greater understanding of the

A
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roles of OPN in muscle remodelling, we examined the
pro-inflammatory effects of OPN on myoblasts. After
incubating myoblasts in the presence of OPN isoforms,
secreted cytokine protein was assessed by IL-6 ELISA.
Here, OPN-a was the most potent inducer of IL-6
production (Fig. 4A). This also appeared to be mediated
by RGD-integrin binding because, as on macrophages, the
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Figure 2. Human OPN-a and OPN-c isoform ratios change with dystrophic severity and mechanical
loading
A, the expression ratio of total OPN (using primers specific to exon 7) to OPN-c (specific to mRNA
sequence spanning from exons 3–5, with exon 4 deleted) in Duchenne muscular dystrophy (DMD) and
Becker’s muscular dystrophy (BMD) vastus lateralis human muscle biopsies (n = 18; all male). Patients were
grouped by histological severity prior to Nanostring mRNA molecule counting, as indicated by total fibre
degeneration and regeneration and inflammatory foci, as assessed via Haematoxylin and Eosin staining.
B, transcript fold changes (Ct ) were quantified before and 24 h after mechanical loading (n = 22,
matched for sex) by qRT-PCR. IL-1β and OPN-c were undetectable in some subjects (n = 3 and n = 4,
respectively) at either baseline or at 24 h and were excluded from analysis. The table below displays
Pearson product–moment correlation coefficients between fold changes in transcripts (Ct values) in
all subjects. ∗ P < 0.05 and ∗∗ P < 0.01 between groups.
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Figure 3. Human primary macrophages show a pro-inflammatory response to recombinant OPN-a in an
RGD-dependent manner
Shown are fold changes of immunoregulatory transcripts from primary human macrophages treated with
1 μg ml−1 OPN isoforms (A) or RGD-sufficient (OPN-a-RGD) and RGD-deficient [RGD→KAE (OPN-a-KAE)]
OPN (B). A, OPN-a increased pro-inflammatory transcripts, whereas OPN-b and OPN-c show less activity.
Statistical significance is presented relative to vehicle control. B, macrophages stimulated with 2 μg ml−1
OPN-a-RGD or OPN-a-KAE show that the pro-inflammatory activity of OPN-a requires RGD-mediated
binding to integrins on macrophages. Statistical significance is compared between treatment conditions.
Expression values after treatment with OPN isoforms are presented as the average fold change relative
to vehicle [polymixin-B (PMB)] treatment for n = 4 healthy male donors. ∗ P < 0.05, ∗∗ P < 0.01 and
∗∗∗ P < 0.001 as assessed via Student’s paired t tests (average donor response).
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OPN-a RGD→KAE mutant induced less IL-6 production
(Fig. 4B).

concentrations were 5.3 pg ml−1 (vehicle) and 4.0 pg ml−1
(TAK-242; Fig. 5).

Human OPN-a cytokine induction is attenuated
in macrophages upon inhibition of TLR4 signalling

Enhancement of monocyte phagocytosis equally
by OPN-a, OPN-b or OPN-c

Given that we observed OPN-induced TNC expression
from macrophages and TNC is a known TLR4 agonist
(Midwood et al. 2009), we sought to determine whether
OPN promoted macrophage cytokine production in
a TLR4-dependent manner. To determine whether
OPN-RGD pro-inflammatory activity occurs via TLR4, a
small molecule intracellular inhibitor of TLR4 signalling,
TAK-242, was used. TAK-242 decreased 98% of IL-6
expression induced by 100 (not shown) and 10 ng ml−1
LPS (Fig. 5) in primary human macrophages. TAK-242
did not affect cell viability (not shown). Induction of
IL-6 by human OPN-a-RGD was likewise blocked by
TAK-242 (93% decrease in IL-6 production), whereas
OPN-a-KAE did not significantly increase IL-6 production
from macrophages. With OPN-a-KAE treatment, the IL-6

Extensive macrophage infiltration is a feature of
dystrophic muscle, where macrophages phagocytose
cellular debris from necrotic myofibres. We tested the
effects of OPN isoforms on macrophage phagocytosis
(Fig. 6). All OPN spliced isoforms increased phagocytosis
of fluorescently conjugated bacterial particles by
6-8-fold (Fig. 6A). OPN-a-RGD and OPN-a-KAE
induced phagocytosis equally, with 8-9-fold increase
in macrophage phagocytosis relative to vehicle (PMB;
Fig. 6B). These results suggest that, in contrast to cytokine
induction, stimulation of phagocytosis is not mediated
by RGD-integrins, and another OPN domain is required
for the phagocytosis that is shared and equally accessible
between the three isoforms.
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Figure 4. OPN isoforms differentially induce pro-inflammatory
cytokine production from human myoblasts in an
RGD-dependent manner
Immortalized human myoblasts were cultured for 48 h with
recombinant human OPN proteins treated with 0.25 or
1.0 μg ml−1 human OPN-a, OPN-b or OPN-c (A) or 1.0 μg ml−1
recombinant human OPNa-RGD or OPNa-KAE (B). Interleukin-6
(IL-6) concentrations in the secreted media were quantified
after 48 h by enzyme-linked immunosorbent assay. Samples
were run in replicates of n = 5.
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Figure 5. Pretreatment of human macrophages with TAK-242,
an inhibitor of Toll-like receptor 4 (TLR4) signalling, inhibits
human OPN-a-mediated IL-6 production
Primary human macrophages were treated with TAK-242
(100 nM) or vehicle (DMSO) for 1 h before stimulation with
1 μg ml−1 OPN-a-RGD and OPN-a-KAE or 10 ng ml−1
lipopolysaccharide (LPS; positive control). Interleukin-6
concentrations in the secreted media were measured at 24 h
by enzyme-linked immunosorbent assay. The
pro-inflammatory activity of OPN-a was largely blocked by
TAK-242. TAK-242 had little effect on OPN-a-KAE activity.
Samples were run in replicates of n = 4.
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et al. 2012). To provide an insight into the role of
OPN-a expression on skeletal muscle transcriptomics,
we performed transcriptional profiling on muscle tissue
sections following intramuscular OPN-a overexpression
in 3-month-old BLA/J mice. We observed that
OPN-a overexpression upregulated transcripts indicative
of pro-inflammatory macrophage recruitment and
activation. When comparing the expression of genes
in TA muscles of mice injected with either OPN-a or
empty plasmid, 432 genes were differentially expressed
at the P < 0.01 level at 7 days postinjection.
Overexpression of OPN-a led to a significant increase in
its own transcript (SPP1; 3.8-fold; P = 0.008; Fig. 7).
OPN-a induction also increased expression of its RGD

Phagocytosis Index
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***

**

**

8
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4
2
Vehicle

Phagocytosis Index
Relative to Vehicle

binding receptors: integrin αV (1.6-fold; P = 0.005)
and integrin α5 (1.5-fold; P = 0.003; not shown).
At 7 days postinjection, the most highly upregulated
pro-inflammatory transcripts by OPN-a included TNC
(3.9-fold, P = 0.004), IL-18 (1.8-fold; P = 0.010),
IL-17 receptor A (1.5-fold; P = 0.007) and CD40
(1.9-fold; P = 0.008; Fig. 7). CX3CR1 expression was also
upregulated 1.9-fold (P = 0.005), suggesting increased
macrophage infiltration after acute injury in response
to OPN-a relative to the empty vector control. The
marker of alternatively activated (less pro-inflammatory)
macrophages, CD163, was also downregulated 2.3-fold
(P = 0.008). Through network analysis, GM-CSF appeared
to be a major upstream regulator of OPN-a-inducible
transcripts within the skeletal muscle (z-score 4.95;
P value of overlap 1.04 × 10−9 ). Together, data from
these two experiments suggest that: (i) OPN-a-inducible
proteins are upregulated in acute muscle injury; and
(ii) intramuscular overexpression of OPN-a promotes
macrophage chemotaxis and pro-inflammatory activation
within the skeletal muscle.
Discussion
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Figure 6. Human OPN-mediated monocyte phagocytosis is
isoform and RGD independent
After 30 min pretreatment with polymixin-B (PMB), primary
human monocytes were treated for 2 h with recombinant OPN
proteins or vehicle (PMB) in the presence of fluorescently
conjugated Escherichia coli particles. Cells were washed, and
cellular fluorescence of non-viable cells was quenched with
Trypan Blue. Phagocytosis is presented as the fold increase in
fluorescence from viable cells relative to vehicle control cells
(PMB). All conditions were normalized for background
fluorescence (E. coli particles only) before calculation of the
fold change relative to vehicle control. A, phagocytosis
induced by 0.5 μg ml−1 OPN spliced isoforms relative to
vehicle (PMB). B, phagocytosis induced by 1.0 μg ml−1
OPN-a-RGD and OPN-a-KAE. All samples were run in replicates
of n = 5, according to the manufacturer’s instructions (Vybrant
Phagocytosis Assay Kit; Life Technologies). Significance is
presented relative to the vehicle control.

OPN is increasingly recognized as an important
mediator of muscle inflammation after damage. A
genetic study showed that gene polymorphisms in OPN
modulate the response of adult volunteer muscle to
inflammation detected by magnetic resonance imaging
after damaging contractions (Barfield et al. 2014),
followed by another study showing that these same
polymorphisms alter the clinical severity of DMD (Bello
et al. 2015). In the present study, we found prominent
upregulation of OPN isoforms in dystrophic muscles
and with mechanical loading, a mild inflammatory
stimulus. This led us to define the pro-inflammatory
effects of OPN spliced isoforms on the skeletal
muscle microenvironment. Macrophages, an extensively
infiltrating immune cell type in dystrophic muscle, were
found to be highly responsive to OPN-a as indicated
by increased pro-inflammatory cytokine production.
OPN-a also exerted some pro-inflammatory effects on
myoblasts. Among the three human OPN isoforms,
OPN-a, OPN-b and OPN-c, cytokine induction was
most prominent in response to OPN-a in macrophages
and myoblasts. In contrast, each of the three isoforms
stimulated monocyte phagocytosis equally well. Through
expression profiling, we observed that intramuscular
overexpression of OPN-a induced expression of
TNC, an endogenous activator of TLR4 signalling.
Furthermore, OPN-a upregulated TNC expression in
human macrophages in vitro. Upon examining the effects
of TLR4 signalling ablation on OPN-mediated cytokine
production, we observed that blockade of TLR4 signalling
attenuated OPN-a-mediated cytokine production in
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human macrophages. Together, our findings suggest that
OPN-a acts as the most pro-inflammatory isoform in the
muscle microenvironment, possibly through induction of
TNC–TLR4 signalling.
In the present study, we compared OPN splice variants
with each other because of distinct properties of the
variants in tumour cells and increased isoform expression
in dystrophic human muscle. Mutating the RGD
sequence of OPN-a revealed that the pro-inflammatory
effect of OPN-a, on both macrophages and myoblasts,
is mediated by the RGD sequence that binds to
integrins including αvβ3, αvβ5 and α5β1. Structural
differences between these isoforms include the presence
or absence of exon 4 or exon 5, while the RGD and
encompassing sequence, TYDGRGDSVVYGLR, in exon
6 is consistently present in the isoforms (Fig. 1A). The
distinct pro-inflammatory effects of the OPN isoforms
observed in this study would probably not occur unless
exon 4 or exon 5 influenced the interaction between

Exp Physiol 101.10 (2016) pp 1285–1300

OPN and integrins. The ability of exon 4 or exon
5 to affect OPN–integrin interactions is supported
by several observations. First, OPN displays enhanced
integrin-mediated function upon polymerization by a
cross-linking enzyme, transglutaminase 2, that covalently
links Gln and Lys residues. OPN-b and OPN-c are
less polymerized than OPN-a (Nishimichi et al. 2011)
owing to loss of Gln residues at exons 4 and 5, which
serve as cross-linking sites. Given that transglutaminase 2
is abundantly expressed by macrophages (Zakrzewicz
et al. 2015) and skeletal muscle (Park et al. 1994), it is
possible that the OPN isoforms were polymerized during
incubation with macrophages and myoblasts. OPN-a
might polymerize sufficiently for cytokine induction
owing to its enhanced ability to undergo polymerization.
Further, polymeric OPN forms a new binding site for
another integrin, α9β1, whose signals might also be less
intensive in OPN-b and OPN-c than OPN-a. Second,
OPN is thought to bind with many proteins through

Figure 7. OPN-a promotes pro-inflammatory macrophage infiltration in vivo
BLA/J mice (n = 3) were injected with OPN-a and an empty vector in contralateral tibialis anterior (TA)
muscles. The TA muscles were harvested 7 days postinjection, and Illumina mRNA expression profiling
was performed. Data are represented as the average transcript fold change by OPN-a relative to
empty vector control. Changes in all transcripts shown were statistically significant (P < 0.05). CSF2,
granulocyte-macrophage colony-stimulating factor (GM-CSF); SPP1, osteopontin; TNC, tenascin-C.
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its naturally disordered domain, including the regions
encompassed at exons 4 and 5. If some proteins in the
culture supernatant from cells or fetal bovine serum bind
differentially to the isoforms, the interactions between
OPN and integrins would not be the same between
isoforms. In contrast, observations of RGD-independent
and equally enhanced monocyte phagocytosis among
isoforms strongly suggest that another OPN receptor,
whose binding site is equally accessible among isoforms,
promotes monocyte phagocytosis. The αxβ2 integrin
might serve such a function because it is abundantly
expressed on macrophages and documented to promote
murine macrophage phagocytosis (Schack et al. 2009).
From expression profiling, our data suggest that OPN-a
promotes TNC- and TLR4-responsive cytokines (IL-1β
and IL-18) in humans and mice. This was evident in
that OPN-a induced TNC and IL-1β expression from
human macrophages. Furthermore, OPN-a expression
was correlated with TNC and IL-1β expression levels in
human muscle following mechanical loading. In mice,
overexpression of OPN-a also increased expression of
TNC and IL-18, another TLR4-responsive cytokine (Rhee
et al. 2013). This led us to examine whether OPN-a
induced cytokine production via TLR4 signalling. We
observed that the pro-inflammatory activity of OPN-a on
human macrophages was attenuated by pretreatment with
a small molecule inhibitor of TLR4 signalling, TAK-242. In
murine RAW264.7 macrophages, TAK-242 inhibits TLR4
signalling by binding to the TIR domain (Cys747) of TLR4
to inhibit downstream signalling activation (Matsunaga
et al. 2011). Our in vitro and in vivo profiling data
suggest that OPN upregulates TNC expression. TNC is
an extracellular matrix protein upregulated in response
to acute injury that promotes TLR4 signalling (Midwood
et al. 2009). Thus, a possible mechanism of OPN-mediated
cytokine production may be induction of TNC–TLR4
signalling. Previous reports have also observed that OPN
ablation attenuates TNC and IL-1β expression levels in a
model of lung injury (Sabo-Attwood et al. 2011), which
further supports this hypothesis. It is additionally possible
that OPN could be acting as a TLR4 agonist itself, because
numerous endogenous activators of TLR4 signalling have
been reported.
In contrast to our findings, OPN isoforms derived from
tumour (MCF-7) cells do not display pro-inflammatory
activity (Sun et al. 2013). Here, Sun et al. observed no effect
of OPN isoforms on LPS-mediated IL-8, IL-6 or IL-12
production from primary human monocytes, whereas
all isoforms decreased tumour necrosis factor-α and
increased IL-10 production. Only OPN-c was observed
to increase the expression of CD163 on monocytes, a
marker of alternative macrophage activation (Kowal et al.
2011), suggesting potential anti-inflammatory activity of
OPN-c. We did not observe an anti-inflammatory effect
of OPN-c per se. However, we observed that OPN-c
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displayed the least pro-inflammatory activity of all of
the OPN-a isoforms. The differential activities of OPN
isoforms may vary widely among tissues and cell types
as a result of multiple post-translational modifications of
OPN and differential OPN receptor expression patterns
(i.e. CD44 versus integrins). Such differences may explain
varying outcomes between studies and highlight a need
to investigate isoform-specific post-translational effects of
OPN in different tissues.
In dystrophic human muscle, we observed that higher
OPN-c expression levels, relative to total OPN, were
associated with reduced histological severity. This suggests
that within the skeletal muscle, OPN-a is likely to be
the primary contributor to the pathological effects of
OPN. Targeting of OPN-a may thus be a useful approach
to reducing OPN-mediated muscle inflammation.
Previously, inhibition of OPN has been shown to reduce
skeletal muscle inflammation in dystrophic mice (Vetrone
et al. 2009) and promote regeneration following acute
injury in aged mice (Paliwal et al. 2012). Targeting OPN-a,
but not OPN-c, signalling in human skeletal muscle might
be a useful therapeutic strategy, because OPN does exert
some positive effects on skeletal muscle regeneration.
Substratum OPN promotes myoblast attachment in
murine cells (Uaesoontrachoon et al. 2008). Conversely,
soluble OPN-a inhibits myotube fusion. These differential
effects of OPN on myoblast proliferation and myotube
fusion are congruent with the pro-inflammatory effects
of OPN, because inflammatory stimuli typically promote
myoblast proliferation and inhibit myotube fusion
(Arnold et al. 2007). As the beneficial effects of OPN
ablation in dystrophic and ageing muscle are presumably
attributable to inhibition of its inflammatory activities
(OPN-a is the only isoform expressed in mice), inhibiting
the inflammatory action of OPN-a while maintaining
some activity of OPN-c might serve as a useful therapy
in humans. Future studies examining the effects of OPN
isoforms on myogenesis (proliferation and fusion) may
further identify the therapeutic utility of OPN isoform
targeting in muscle disease.
In mdx mice, ablation of OPN attenuates muscle fibrosis
and TGFβ expression (Vetrone et al. 2009). However, we
did not observe a direct effect of OPN on TGFβ production
in macrophages or myoblasts (not shown). Based on our
findings, the ability of OPN to promote fibrosis is likely
to be attributable to its pro-inflammatory, chemotactic
and phagocytic activities, rather than directly inducing
TGFβ production from myoblasts or macrophages. This is
supported, because genetic ablation of TLR4 reduces both
inflammation and fibrosis in mdx mice, suggesting that
inflammation, particularly innate immunity, contributes
to muscle fibrosis in the context of dystrophin deficiency
(Giordano et al. 2015). However, it is possible that OPN
expression in the muscle microenvironment promotes
TGFβ secretion by another cell type.
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Limitations

In dystrophic human muscle, this study was limited by
a conservative sample size. Future profiling of OPN-a
and OPN-c expression levels and their correlation with
muscle pathology might elucidate the utility of OPN
isoform ratios as a biomarker of disease severity. We did
not specifically examine the effects of inhibiting TNC
on OPN-mediated inflammatory cytokine production.
Further studies investigating OPN–TNC signalling are
thus warranted. Additionally, it is unknown whether
OPN isoform expression and function are fibre-type
specific. Future studies examining the effects of OPN
overexpression in murine muscle groups with varying
fibre-type composition may thus be of interest.
Together, our data suggest that OPN is an
important mediator of muscle inflammation, whereby
its expression in response to mechanical loading and in
dystrophin deficiency contributes to both macrophage
and muscle cytokine production. Furthermore, our data
support a body of literature indicating that localized
myofibre OPN-a expression increases inflammation by
promoting pro-inflammatory monocyte recruitment and
macrophage activation to damaged myofibres. The
pro-inflammatory activity of OPN-a may be mediated,
in part, by induction of TNC–TLR4 signalling. Our data
further suggest differential activities of human spliced
OPN isoforms and suggest that targeting RGD-mediated
integrin signalling and/or transglutamination might
attenuate the pro-inflammatory activity of OPN-a within
the skeletal muscle microenvironment.
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